Rhythm Pharmaceuticals (RYTM) Short-term Investments (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Short-term Investments data on file, last reported at $278.5 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $278.5 million, up 33.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $278.5 million (up 33.64% YoY), and the FY2025 annual result was $334.6 million, up 44.6% from the prior year.
• Short-term Investments fell to $278.5 million in Q1 2026 per RYTM's latest filing, from $334.6 million in the prior quarter.
• Over five years, Short-term Investments peaked at $364.0 million in Q3 2025 and troughed at $122.4 million in Q2 2022.
• A 5-year average of $209.1 million and a median of $205.6 million in 2022 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments tumbled 59.04% in 2022, then jumped 45.09% in 2025.
• A 5-year view of Short-term Investments shows it stood at $205.6 million in 2022, then increased by 4.94% to $215.8 million in 2023, then climbed by 7.26% to $231.4 million in 2024, then surged by 44.6% to $334.6 million in 2025, then decreased by 16.78% to $278.5 million in 2026.
• Business Quant data shows RYTM's Short-term Investments at $278.5 million in Q1 2026, $334.6 million in Q4 2025, and $364.0 million in Q3 2025.